Cramer says Bluebird Bio is too speculative for him but he likes Enterprise Products Partners.
The market is fearful. Use that fear to buy, Cramer says.
Bluebird Bio (BLUE) stock was raised to 'conviction buy' at Goldman on Thursday.
Bluebird Bio (BLUE) could be a takeover target for Takeda Pharmaceutical (TKPYY), Citi said on Wednesday.